151.90
Schlusskurs vom Vortag:
$148.09
Offen:
$148.51
24-Stunden-Volumen:
293.14K
Relative Volume:
0.83
Marktkapitalisierung:
$4.39B
Einnahmen:
$290.51M
Nettoeinkommen (Verlust:
$89.16M
KGV:
50.80
EPS:
2.99
Netto-Cashflow:
$119.18M
1W Leistung:
+2.82%
1M Leistung:
+14.68%
6M Leistung:
-1.02%
1J Leistung:
-26.57%
Krystal Biotech Inc Stock (KRYS) Company Profile
Firmenname
Krystal Biotech Inc
Sektor
Branche
Telefon
(412) 586-5830
Adresse
2100 WHARTON STREET, PITTSBURGH, PA
Vergleichen Sie KRYS mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
KRYS
Krystal Biotech Inc
|
151.90 | 4.27B | 290.51M | 89.16M | 119.18M | 2.99 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-03-05 | Eingeleitet | Jefferies | Buy |
2024-08-06 | Herabstufung | Citigroup | Buy → Neutral |
2023-11-20 | Eingeleitet | Goldman | Buy |
2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
2023-10-12 | Eingeleitet | Citigroup | Buy |
2023-09-07 | Eingeleitet | Berenberg | Buy |
2023-04-18 | Eingeleitet | Stifel | Buy |
2023-02-28 | Hochstufung | Goldman | Neutral → Buy |
2022-08-25 | Herabstufung | Goldman | Buy → Neutral |
2022-01-18 | Eingeleitet | BofA Securities | Buy |
2021-07-20 | Hochstufung | Goldman | Neutral → Buy |
2020-09-18 | Eingeleitet | B. Riley FBR | Buy |
2020-06-04 | Eingeleitet | Evercore ISI | Outperform |
2019-09-24 | Eingeleitet | Goldman | Neutral |
2019-08-06 | Bestätigt | H.C. Wainwright | Buy |
2019-06-24 | Bestätigt | Chardan Capital Markets | Buy |
2019-06-24 | Bestätigt | H.C. Wainwright | Buy |
2019-05-30 | Eingeleitet | Guggenheim | Buy |
2018-09-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Krystal Biotech Inc Aktie (KRYS) Neueste Nachrichten
What analysts say about Krystal Biotech Inc. stockFast-track wealth growth - jammulinksnews.com
What drives Krystal Biotech Inc. stock priceRapidly growing investment returns - jammulinksnews.com
Krystal Biotech Inc. Stock Analysis and ForecastDynamic growth stocks - Autocar Professional
Is Krystal Biotech Inc. a good long term investmentOutstanding capital returns - jammulinksnews.com
What makes Krystal Biotech Inc. stock price move sharplyTop Gaining Low Risk Assets - Newser
Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Nisa Investment Advisors LLC - Defense World
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today - Benzinga
Hedge Fund and Insider Trading News: Bobby Jain, Bill Ackman, Ken Griffin, Sylebra Capital Management, Millennium Management, Krystal Biotech Inc (KRYS), and More - Insider Monkey
William Blair Predicts Lower Earnings for Krystal Biotech - Defense World
Krishnan Krish S, Krystal Biotech CEO, sells $5.39 million in stock - Investing.com Canada
Krystal biotech (KRYS) director Suma Krishnan sells $5.39m in stock By Investing.com - Investing.com South Africa
Krystal biotech (KRYS) director Suma Krishnan sells $5.39m in stock - Investing.com Australia
Citi Maintains Krystal Biotech(KRYS.US) With Hold Rating, Raises Target Price to $176 - 富途牛牛
Krystal Biotech, Inc. (NASDAQ:KRYS) Position Trimmed by Bank of New York Mellon Corp - Defense World
why krystal biotech inc. stock attracts strong analyst attentionControlled Risk High Reward Plan - Newser
M&T Bank Corp Purchases New Shares in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Krystal Biotech FY2025 EPS Estimate Lowered by William Blair - Defense World
Why Krystal Biotech Inc. stock attracts strong analyst attentionFree Stock Investment Discussion Area - Newser
How Krystal Biotech Inc. stock performs during market volatilityPortfolio Boosting Stock Alerts - Newser
Krystal Biotech doses first patient in EMERALD-1 phase 1/2 trial for neurotrophic keratitis - Ophthalmology Times
Teacher Retirement System of Texas Has $1.05 Million Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
William Blair Forecasts Lower Earnings for Krystal Biotech - Defense World
William Blair Expects Lower Earnings for Krystal Biotech - Defense World
KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up - Yahoo Finance
Krystal Biotech begins phase 1/2 trial of eye drop gene therapy for NK By Investing.com - Investing.com South Africa
Krystal Biotech begins phase 1/2 trial of eye drop gene therapy for NK - Investing.com Nigeria
Transcript : Krystal Biotech, Inc.Special Call - MarketScreener
Krystal Biotech Begins Phase 1/2 Trial for KB801 - TipRanks
Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis - The Manila Times
Krystal Biotech Initiates First Patient Dosing in Phase 1/2 EMERALD-1 Trial for KB801 in Neurotrophic Keratitis - Nasdaq
Revolutionary Eye Drop Gene Therapy: Krystal Biotech Targets 68,000 Patient NK Market in New Trial - Stock Titan
New York State Teachers Retirement System Grows Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Allspring Global Investments Holdings LLC Decreases Stake in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Finanzdaten der Krystal Biotech Inc-Aktie (KRYS)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):